Cidara Therapeutics Inc buy shadow
Start price
13.04.21
/
0%
€1.83
Target price
13.04.22
-
Performance (%)
-60.43%
End price
14.04.22
€0.72
Summary
This prediction ended on 14.04.22 with a price of €0.72. The BUY prediction by shadow for Cidara Therapeutics Inc performed very badly with a performance of -60.43%. This prediction was marked as speculative and is excluded from shadow's performance statistics.Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Cidara Therapeutics Inc | - | - | - | - |
| iShares Core DAX® | 1.662% | 4.835% | 17.361% | 19.329% |
| iShares Nasdaq 100 | 0.667% | 0.000% | 38.234% | 55.157% |
| iShares Nikkei 225® | -2.139% | -4.786% | 13.099% | 7.393% |
| iShares S&P 500 | 0.564% | 0.775% | 29.181% | 46.527% |
According to shadow what are the pros and cons of Cidara Therapeutics Inc for the foreseeable future?
Pros
Revenue growth >5% per year expected
Capable Management
Innovative
Cons
Probably not worthwhile Investment
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Low dividend yield expected
negative Cash Flow expected
Bad rating
Little Investments for future growth
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Bad culture
Few uniques
Dependend from some customers or products
Growths slower than the competition
Sustainability is little important
high free float
Higher risks for its business
Below average Marketposition
Significant cyclical dependencies
Business model of the past or high risk
Little known brand
High valuation
Comments by shadow for this prediction
In the thread Cidara Therapeutics Inc diskutieren
Buy Cidara Therapeutics Inc
In the thread Trading Cidara Therapeutics Inc
Die von shadow gewählte maximale Laufzeit wurde überschritten